Loading
8 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Incidental gallbladder cancer is cancer the pathologist finds in a gallbladder removed for gallstones or inflammation, when nobody suspected it. It is the commonest way this cancer is found early enough to cure. Whether a second operation is needed depends on how deep the tumour went: none for the earliest layers, a radical operation at a specialist centre for T1b or deeper.
Between one in 400 and one in 110 gallbladders removed for presumed benign disease contains a cancer (0.25 to 0.89 percent; Soreide 2019), and the share rises steeply with age (0.08 percent under 60 versus 0.67 percent over 60 in Denmark, where every specimen is examined; the surgeon had noted macroscopic changes in 27 of 28 cancers, Lerche-Jorgensen 2025). About half are pT2 and a third pT1. Patients whose cancer is confined to the mucosa (T1a or less) have five-year survival of up to 100 percent after the cholecystectomy alone; for T1b or deeper tumours re-resection is recommended, though its type, extent and timing remain debated (Soreide 2019; AHPBA consensus, Aloia 2015). Ten US academic centres found re-resection between 4 and 8 weeks after the first operation gave the longest survival (median 40.4 months, against 17.4 months under 4 weeks and 22.4 months over 8 weeks), the interval allowing new CT or MRI and PET-CT, which can show residual or distant disease and prevent a futile operation (Ethun 2017; Soreide 2019). Perforation of the gallbladder at the first operation raises the risk of dissemination, and the risk of peritoneal spread rises with each T category. Port-site metastases occurred in 18.6 percent of laparoscopic cases before 2000 and 10.3 percent since (Berger-Richardson 2017); routine excision of the port sites does not improve survival (Soreide 2019). Routine staging laparoscopy before re-resection is not needed for every stage. Adjuvant chemotherapy after re-resection is poorly documented and probably underused (Soreide 2019).
Getting patients to the right place is the weak link: in 27 Dutch secondary hospitals only 53.9 percent of 243 patients eligible for re-resection (pT1b to pT3, M0) were referred to a tertiary centre, and in nearly half of the non-referred the reason was not documented (van Dooren 2024). In the UK the specialist hepatobiliary multidisciplinary team is the route; two UK units have described their approach to suspected cancer, using intraoperative frozen section to decide on extending surgery at the first operation (Chan 2022, Liverpool; Banh 2024, London). The UK pathway page carries referral detail; this page covers what the finding means.
| Setting | Approach | Guideline |
|---|---|---|
| Tis or T1a with a clear cystic duct margin | No further surgery; the simple cholecystectomy is treatment enough. | not mapped |
| T1b, T2 or T3, no metastases | Referral to a hepatobiliary centre; interval CT or MRI and PET-CT; radical cholecystectomy (liver bed plus portal lymphadenectomy) at 4 to 8 weeks, with bile duct resection only for a positive cystic duct margin; port sites not routinely excised; adjuvant capecitabine after. | not mapped |
| Residual disease found on interval imaging or at re-operation | Systemic treatment as for advanced gallbladder cancer. | not mapped |